Other potential adverse effects were also taken into account such as the risk of cardiac failure, factures, and bladder cancer associated with thiazolidinediones 35-37 and that of urogenital tract infections associated with SGLT2 inhibitors 38. The gene discussed is SLC5A2; the disease is heart failure.